Medical Device Regulation (EU)

Medical Device Regulation (EU)
Title	Medical Device Regulation (EU)
Type	Regulation
Number	Regulation (EU) 2017/745
Adopted	2017-04-05
Entered into force	2017-05-05
Applicability	2021-05-26
Repeals	Council Directive 93/42/EEC; Council Directive 90/385/EEC
Institution	European Parliament; Council of the European Union

Medical Device Regulation (EU)

The Medical Device Regulation (EU) is a comprehensive legislative act adopted by the European Parliament and the Council of the European Union to harmonize requirements for medical devices across the European Union. It replaced earlier directives to strengthen pre-market scrutiny, post-market surveillance, and traceability while enhancing patient safety and market transparency. The regulation affects manufacturers, notified bodies, competent authorities in Member States, and economic operators throughout the European Economic Area.

Background and Scope

The regulation was developed following high-profile device safety incidents and recommendations by bodies such as the European Commission, the European Medicines Agency, and reports from the European Court of Justice and the European Parliament inquiries. It expands the scope beyond traditional devices to include in vitro diagnostic medical devices (partially addressed separately by Regulation (EU) 2017/746), software-as-a-medical-device questioned in discussions by World Health Organization task forces, and certain aesthetic implants noted in debates involving the Council of Europe. The MDR sets out general safety and performance requirements, traceability via the European Database on Medical Devices initiative, and strengthens roles of notified authorities like national competent authorities in Germany, France, Italy, and Spain.

Legislative Framework and Key Provisions

Key provisions originated from negotiations among the European Commission, the European Parliament committees, and the Council of the European Union delegations, culminating in Regulation (EU) 2017/745. The MDR codifies obligations for clinical evaluation, technical documentation, and risk classification informed by standards from organizations such as International Organization for Standardization and European Committee for Standardization. It mandates Unique Device Identification (UDI) systems aligned with global efforts from the International Medical Device Regulators Forum and references conformity routes influenced by jurisprudence of the Court of Justice of the European Union.

Classification, Conformity Assessment, and CE Marking

The MDR revises device classification rules, increasing the number of devices in higher risk classes, a change that echoed concerns raised in hearings by the European Economic and Social Committee and industry stakeholders like MedTech Europe. Conformity assessment procedures, often performed by notified bodies designated under national schemes such as those administered by Bundesinstitut für Arzneimittel und Medizinprodukte or Agence nationale de sécurité du médicament et des produits de santé, determine eligibility for CE marking. The CE mark remains the indicator of conformity required for market access across the European Free Trade Association states participating in the internal market.

Post‑market Surveillance and Vigilance

The MDR enhances post-market surveillance obligations, creating proactive systems for periodic safety update reports, trend reporting, and corrective actions, aligning with pharmacovigilance concepts championed by the European Medicines Agency. Vigilance reporting to national competent authorities must be timely, with serious incidents and field safety corrective actions tracked through databases coordinated with the European Commission and interoperable registries referenced by the World Health Organization. Implant cards and patient registries, similar to registries for joint replacements championed by stakeholders in Sweden and Finland, are emphasized.

Notified Bodies, Clinical Evaluation, and Performance Studies

Designation and oversight of notified bodies are tightened, with assessments conducted by national accreditation bodies such as those participating in the European Cooperation for Accreditation. Notified bodies must evaluate clinical evidence, drawing on guidance from the European Commission and documents referenced by the European Society of Cardiology and European Society of Radiology for device-specific studies. The MDR requires well-designed clinical performance studies and acceptance criteria reviewed by competent authorities and ethics committees similar to those guided by European Network of Research Ethics Committees.

Market Access, Economic Operators, and Labelling Requirements

The regulation defines roles for manufacturers, authorised representatives, importers, and distributors—economic operators whose responsibilities were debated in stakeholder consultations with entities like BusinessEurope and European Association of Medical Devices Notified Bodies. Labelling and instructions for use must meet language and content requirements specified by the MDR, incorporate UDI mechanisms, and include information similar to clinical data transparency initiatives promoted by the European Medicines Agency. Authorized representatives in United Kingdom transitions and entities in Norway have been focal points in adaptation dialogues.

Implementation Challenges and Impact on Stakeholders

Implementation involved transitional provisions, capacity constraints among notified bodies highlighted in reviews by the European Court of Auditors, and compliance costs reported by manufacturers and trade groups such as European Federation of Pharmaceutical Industries and Associations. Hospitals, clinicians, and patients represented by organizations like European Patients' Forum have noted improved safety expectations but also concerns about device availability and innovation impacts raised by research institutions such as Imperial College London and Karolinska Institutet. Ongoing regulatory cooperation among Member States, coordination via the European Commission, and engagement with global partners like the United States Food and Drug Administration shape the MDR's practical outcomes.

Category:European Union regulations